{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:15:21Z","timestamp":1790727321523,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100009431","name":"Baxalta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,8,1]]},"DOI":"10.1007\/s12325-019-00988-5","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:00:28Z","timestamp":1559044828000},"page":"2106-2121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Development of a Lyophilized Formulation of Pegaspargase and Comparability Versus Liquid Pegaspargase"],"prefix":"10.1007","volume":"36","author":[{"given":"Alexander M.","family":"Faschinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Sessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"issue":"10","key":"988_CR1","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.6004\/jnccn.2015.0153","volume":"13","author":"JC Alvarnas","year":"2015","unstructured":"Alvarnas JC, Brown PA, Aoun P, et al. Acute lymphoblastic leukemia, version 2.2015. J Natl Compr Cancer Netw. 2015;13(10):1240\u201379.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"suppl 5","key":"988_CR2","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","volume":"27","author":"D Hoelzer","year":"2016","unstructured":"Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v69\u201382.","journal-title":"Ann Oncol"},{"issue":"11","key":"988_CR3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.20452\/pamw.518","volume":"118","author":"B Piatkowska-Jakubas","year":"2008","unstructured":"Piatkowska-Jakubas B, Krawczyk-Kulis M, Giebel S, et al. Use of l-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group. Pol Arch Med Wewn. 2008;118(11):664\u20139.","journal-title":"Pol Arch Med Wewn"},{"issue":"2","key":"988_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/cncr.25489","volume":"117","author":"R Pieters","year":"2011","unstructured":"Pieters R, Hunger SP, Boos J, et al. l-Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer. 2011;117(2):238\u201349.","journal-title":"Cancer"},{"key":"988_CR5","unstructured":"Jazz Pharmaceuticals Inc. Erwinase\u00ae Highlights of Prescribing Information 2016. https:\/\/erwinaze.com\/ERWINAZEPI.pdf. Accessed Dec 2017."},{"issue":"2","key":"988_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1128\/aem.33.2.257-261.1977","volume":"33","author":"WR Barnes","year":"1977","unstructured":"Barnes WR, Dorn GL, Vela GR. Effect of culture conditions on synthesis of l-asparaginase by Escherichia coli A-1. Appl Environ Microbiol. 1977;33(2):257\u201361.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"988_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2958.1993.tb01677.x","volume":"9","author":"MP Jennings","year":"1993","unstructured":"Jennings MP, Beacham IR. Co-dependent positive regulation of the ansB promoter of Escherichia coli by CRP and the FNR protein: a molecular analysis. Mol Microbiol. 1993;9(1):155\u201364.","journal-title":"Mol Microbiol"},{"issue":"6","key":"988_CR8","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1128\/jb.95.6.2117-2123.1968","volume":"95","author":"J Roberts","year":"1968","unstructured":"Roberts J, Burson G, Hill JM. New procedures for purification of l-asparaginase with high yield from Escherichia coli. J Bacteriol. 1968;95(6):2117\u201323.","journal-title":"J Bacteriol"},{"key":"988_CR9","first-page":"185","volume":"39","author":"JC Wriston Jr","year":"1973","unstructured":"Wriston JC Jr, Yellin TO. l-Asparaginase: a review. Adv Enzymol Relat Areas Mol Biol. 1973;39:185\u2013248.","journal-title":"Adv Enzymol Relat Areas Mol Biol"},{"issue":"4","key":"988_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/BF00409287","volume":"92","author":"J Netrval","year":"1973","unstructured":"Netrval J. Effect of organic and amino acids on l-asparaginase production by Escherichia coli. Arch Mikrobiol. 1973;92(4):345\u201352.","journal-title":"Arch Mikrobiol"},{"issue":"8","key":"988_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1634\/theoncologist.12-8-991","volume":"12","author":"PA Dinndorf","year":"2007","unstructured":"Dinndorf PA, Gootenberg J, Cohen MH, Keegan P, Pazdur R. FDA drug approval summary: pegaspargase (Oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12(8):991\u20138.","journal-title":"Oncologist"},{"issue":"2","key":"988_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00280-014-2506-9","volume":"74","author":"S Borghorst","year":"2014","unstructured":"Borghorst S, Hempel G, Poppenborg S, Franke D, Konig T, Baumgart J. Comparative pharmacokinetic\/pharmacodynamic characterisation of a new pegylated recombinant E.\u00a0coli l-asparaginase preparation (MC0609) in Beagle dog. Cancer Chemother Pharmacol. 2014;74(2):367\u201378.","journal-title":"Cancer Chemother Pharmacol"},{"key":"988_CR13","doi-asserted-by":"crossref","unstructured":"Rau RE, Dreyer Z, Choi MR, et al. Outcome of pediatric patients with acute lymphoblastic leukemia\/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2018;65(3):e26873.","DOI":"10.1002\/pbc.26873"},{"issue":"5","key":"988_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10637-014-0102-9","volume":"32","author":"WW Chien","year":"2014","unstructured":"Chien WW, Allas S, Rachinel N, et al. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived l-asparaginase. Invest New Drugs. 2014;32(5):795\u2013805.","journal-title":"Invest New Drugs"},{"issue":"Suppl 1","key":"988_CR15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/CCO.0b013e32835d7d85","volume":"25","author":"C Rizzari","year":"2013","unstructured":"Rizzari C, Conter V, Stary J, Colombini A, Moericke A, Schrappe M. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol. 2013;25(Suppl 1):S1\u20139.","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"988_CR16","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.1993.11.9.1780","volume":"11","author":"BL Asselin","year":"1993","unstructured":"Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993;11(9):1780\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"988_CR17","first-page":"373","volume":"1","author":"YK Park","year":"1981","unstructured":"Park YK, Abuchowski A, Davis S, Davis F. Pharmacology of Escherichia coli-l-asparaginase polyethylene glycol adduct. Anticancer Res. 1981;1(6):373\u20136.","journal-title":"Anticancer Res"},{"issue":"7","key":"988_CR18","first-page":"1964","volume":"119","author":"N Patel","year":"2009","unstructured":"Patel N, Krishnan S, Offman MN, et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase. J Clin Invest. 2009;119(7):1964\u201373.","journal-title":"J Clin Invest"},{"issue":"6","key":"988_CR19","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","volume":"99","author":"VI Avramis","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood. 2002;99(6):1986\u201394.","journal-title":"Blood"},{"issue":"6","key":"988_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s13318-017-0410-5","volume":"42","author":"G W\u00fcrthwein","year":"2017","unstructured":"W\u00fcrthwein G, Lanvers-Kaminsky C, Hempel G, et al. Population pharmacokinetics to model the time-varying clearance of the PEGylated asparaginase Oncaspar\u00ae in children with acute lymphoblastic leukemia. Eur J Drug Metab Pharmacokinet. 2017;42(6):955\u201363.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"988_CR21","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","volume":"105","author":"PL Turecek","year":"2016","unstructured":"Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105(2):460\u201375.","journal-title":"J Pharm Sci"},{"issue":"10","key":"988_CR22","doi-asserted-by":"publisher","first-page":"25831","DOI":"10.3390\/ijms161025831","volume":"16","author":"JK Dozier","year":"2015","unstructured":"Dozier JK, Distefano MD. Site-specific PEGylation of therapeutic proteins. Int J Mol Sci. 2015;16(10):25831\u201364.","journal-title":"Int J Mol Sci"},{"key":"988_CR23","unstructured":"Shire Pharmaceuticals. Oncaspar summary of product characteristics 2017. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003789\/WC500200735.pdf. Accessed December 2017."},{"issue":"3","key":"988_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2174\/138920112799361990","volume":"13","author":"RL Remmele","year":"2012","unstructured":"Remmele RL, Krishnan S, Callahan WJ. Development of stable lyophilized protein drug products. Curr Pharm Biotechnol. 2012;13(3):471\u201396.","journal-title":"Curr Pharm Biotechnol"},{"issue":"4","key":"988_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3109\/10837450.2012.705295","volume":"18","author":"JM Davis","year":"2013","unstructured":"Davis JM, Zhang N, Payne RW, et al. Stability of lyophilized sucrose formulations of an IgG1: subvisible particle formation. Pharm Dev Technol. 2013;18(4):883\u201396.","journal-title":"Pharm Dev Technol"},{"issue":"4","key":"988_CR26","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/jps.21530","volume":"98","author":"JF Carpenter","year":"2009","unstructured":"Carpenter JF, Randolph TW, Jiskoot W, et al. Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci. 2009;98(4):1201\u20135.","journal-title":"J Pharm Sci"},{"issue":"10","key":"988_CR27","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1023\/A:1012193326789","volume":"14","author":"A Braun","year":"1997","unstructured":"Braun A, Kwee L, Labow MA, Alsenz J. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res. 1997;14(10):1472\u20138.","journal-title":"Pharm Res"},{"issue":"1","key":"988_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/jps.22753","volume":"101","author":"BM Murphy","year":"2012","unstructured":"Murphy BM, Zhang N, Payne RW, et al. Structure, stability, and mobility of a lyophilized IgG1 monoclonal antibody as determined using second-derivative infrared spectroscopy. J Pharm Sci. 2012;101(1):81\u201391.","journal-title":"J Pharm Sci"},{"issue":"2","key":"988_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/jps.24242","volume":"104","author":"S Telikepalli","year":"2015","unstructured":"Telikepalli S, Kumru OS, Kim JH, et al. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress. J Pharm Sci. 2015;104(2):495\u2013507.","journal-title":"J Pharm Sci"},{"issue":"1","key":"988_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0031-6865(99)00009-6","volume":"74","author":"AL Stecher","year":"1999","unstructured":"Stecher AL, de Deus PM, Polikarpov I, Abrah\u00e3o-Neto J. Stability of l-asparaginase: an enzyme used in leukemia treatment. Pharm Acta Helv. 1999;74(1):1\u20139.","journal-title":"Pharm Acta Helv"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00988-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-019-00988-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00988-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T19:13:57Z","timestamp":1721330037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-019-00988-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8,1]]}},"alternative-id":["988"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00988-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"1 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}